The CHMP supports the use of Pfizer’s (PFE) oral COVID-19 drug, Paxlovid, to treat high-risk patients even though it has not received conditional authorization from the European Commission.
The CHMP supports the use of Pfizer’s (PFE) oral COVID-19 drug, Paxlovid, to treat high-risk patients even though it has not received conditional authorization from the European Commission.